Translation results
The AstraZeneca vaccine and batches withdrawn, in Italy and in several European countries In Italy, the Medicines Agency has banned the use of a batch of AstraZeneca vaccine as a precaution after "adverse events" were recorded, but the link with the vaccine has not yet been ascertained. In other European countries the suspension was decided, for a different batch The AstraZeneca vaccine and batches withdrawn, in Italy and in various European countries shadow Aifa, the Italian drug agency, has blocked the use of a batch of AstraZeneca's Covid vaccine. The decision, relating to a single lot - from code ABV2856 - came following the reporting of some «serious adverse events», in «temporal concomitance with the administration of doses of the vaccine». Aifa claims that this decision was taken as a precautionary measure: in other words, there is no evidence that the vaccine caused the "adverse events" - circulatory problems attributable to thrombosis - while, at the moment, these are reports related to " temporal concomitance ". In its statement, Aifa writes that "at the moment no causal link has been established between the administration of the vaccine and these events", and explains that it is "carrying out all the necessary veracities, acquiring clinical documentation in close collaboration with the NAS and the competent authorities". The samples of the withdrawn batch "will be analyzed by the Istituto Superiore di Sanità". According to the Ansa agency, doses of the AstraZeneca vaccine belonging to batch ABV2856 were also administered in the Aosta Valley between 10 and 19 February. The health director of the Calle d’Aostra Local Health Authority Maurizio Castelli explained that no particular side effects were found. The Ema - the European Medicines Agency - has clarified that, while the investigations continue, the administration of the vaccine produced by the Anglo-Swedish pharmaceutical company is to be considered safe and can continue, and that the benefits of the anti Covid vaccine developed by AstraZeneca outweigh the risks. The Italian Prime Minister, Mario Draghi, had a telephone conversation with the President of the European Commission, Ursula Von der Leyen. From the conversation it emerged that there is no evidence of a link between the cases of thrombosis recorded in Europe and the administration of the AstraZeneca vaccine. What are the "adverse events" in Italy Aifa did not specify the "adverse events" that led to the precautionary suspension. The Reuters agency, which cites sources familiar with the matter, explains that these are two deaths recorded in Sicily. One of these cases concerns a soldier serving in Augusta, Stefano Paternò, 43, originally from Corleone, but residing in Misterbianco (Catania). For his death there are about ten suspects, accused of manslaughter. Another case is that of Davide Villa, 50, a police officer. Villa and Paternò had received the AstraZeneca vaccine: the first a few days before, the second the day before death. The doses belonged to the batch withdrawn from AIFA. There is no confirmation - it must be repeated - that these deaths are attributable to the vaccine. Denmark's decision on the AstraZeneca vaccine On the same day today, Denmark and 6 other European countries decided to suspend the use of the AstraZeneca vaccine. This decision - the Danish authorities explained - is linked to reports of "serious adverse events" recorded in Denmark, also in this case thrombosis, for which at the moment the causal link with the administration of the vaccine is not certain. In particular, in Denmark one of these adverse events is related to a death. Denmark has decided to suspend the use of the AstraZeneca vaccine for 14 days, and specified that this choice does not at all imply that the AstraZeneca vaccine will no longer be used in the country at all. The lot we are talking about in this case is different from the one distributed in Italy, and was instead distributed in 17 European countries. Seven of these countries - Estonia, Lithuania, Luxembourg, Latvia, Norway, Iceland and Denmark - have decided to suspend the use of the AstraZeneca vaccine. Spain claimed that it has not registered any cases of thrombosis, and that it will continue to use the vaccine produced by the Anglo-Swedish company on a regular basis. The EMA's response on thrombosis cases EMA, the European Medicines Agency, reported that the risk of blood clots is no greater in vaccinated people. "The information available so far," said Ema, "indicates that the number of thromboembolic events in vaccinated people is no higher than that observed in the rest of the population.